Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced on Saturday the first results from the … Continue reading Phase 3 Results for Adjuvant Treatment with Merck’s KEYTRUDA® Show Superior RFS in Patients With Resected High-Risk Stage II Melanoma
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed